Highlights

  • Canaccord Genuity initiated a Buy rating with a target of 325 GBX.
  • Itaconix is up 11.63% year-to-date, despite a 26.15% decline over the past year.
  • FY 2025 revenues surged 59% YoY to USD 10.3 million, surpassing USD 10 million for the first time.
  • The company expects continued revenue growth supported by a growing customer pipeline and scalable, capital-efficient operations.

Itaconix PLC (LSE:ITX) has moved into sharper focus on the London market after attracting a bullish call from Canaccord Genuity, marking a notable moment for the AIM-listed specialty chemicals company. The stock was trading at 120.00 GBX at the close on 16 January, up 4.35% on the day, reflecting renewed investor interest. Despite the recent uptick, the shares remain down 26.15% over the past year, even as they have gained 11.63% on a year-to-date basis. While the company’s shares have struggled over a 12-month horizon, the positive year-to-date performance suggests improving sentiment in early 2026.

Buy Rating Signals Confidence from Analysts

Canaccord Genuity has initiated a “Buy” rating on Itaconix, setting a target price of 325 GBX. The target implies substantial upside from current levels and places the brokerage among the more optimistic voices covering the stock.

Operational Update Adds Context

Alongside analyst attention, Itaconix recently released a trading update for the year ended 31 December 2025. Revenues soared 59% year-on-year to USD 10.3 million, surpassing USD 10 million for the first time (FY 2024: USD 6.5 million). This milestone was driven by a third straight record half-year, with H2 2025 revenues reaching USD 5.5 million, up from USD 4.8 million in H2 2024.

Broad-Based Growth Across Markets

Expansion came from both longstanding and new customers, across key applications and global regions. Surging demand for Itaconix's patented polymers reflects major consumer goods manufacturers' shift toward sustainable, high-performing ingredients. These innovations boost formulations in detergents, hygiene, and beauty products, delivering superior performance and value. Enhanced commercial momentum has fueled investments in demand generation and 2026 support.

Positive Outlook for 2026

The Board is confident in 2026 prospects, positioning Itaconix for ongoing revenue growth. Strengths include a robust customer pipeline, wider product adoption, and a scalable, capital-light model that ensures efficiency and agility.